| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9584 | (R)-(-)-Rolipram | (R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor with IC50 of 0.22 uM; 2.5-fold more potent than (+)-rolipram (IC50= 2.58 uM) in inhibiting membrane-bound PDE 4. |
|
| DCAPI1409 | Maxacalcitol | 22-Oxacalcitriol is a Vitamin D3 analog which is Non-calcemic as well as a VDR ligand. 22-Oxacalcitriol has been shown to decrease parathyroid hormone (PTH) mRNA expression in vitro. Additionally has been noted to exhibit similar effects to calcitriol in |
|
| DC11530 | Tapinarof (Benvitimod; GSK2894512) Featured | Tapinarof (WBI-1001) is a natural aryl hydrocarbon receptor (AhR) agonist with an EC50 of 13 nM. Tapinarof resolves skin inflammation in mice. |
|
| DC11910 | IPL-576092 | A novel orally active, anti-inflammatory compound that inhibits leukocyte infiltration and changes in lung function in response to allergen challenge. |
|
| DC11868 | Freselestat | A potent, selective and orally active human neutrophil elastase (HNE) inhibitor with Ki of 12 nM. |
|
| DC10417 | Acumapimod (BCT197) Featured | Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α. |
|
| DC11886 | Adavivint Featured | Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro |
|
| DC11097 | ADX-102 (Reproxalap;NS-2) Featured | ADX-102 (Reproxalap, NS-2) is a novel small molecule immunomodulator that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain; DX-102 is a promising agent for the treatment of dry eye disease. |
|
| DCAPI1467 | Alcaftadine | Alcaftadine |
|
| DC9406 | Ampiroxicam | Ampiroxicam(CP65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug. |
|
| DC7815 | Crisaborole(AN-2728) Featured | AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines. |
|
| DC7063 | Apremilast Featured | Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM. |
|
| DC5014 | AVL-292 Featured | AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
|
| DC11802 | AX-024 free base Featured | AX-024 is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A. |
|
| DC10545 | AX-024 HCl Featured | AX-024 is the first-in-class inhibitor of T cell receptor (TCR); AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). |
|
| DC10724 | AZD2098 Featured | AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research. |
|
| DC11723 | AZD-7986(Brensocatib) Featured | AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4. |
|
| DC10425 | AZD9056 hydrochloride | AZD9056 is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases. |
|
| DC11541 | AZD-9567 | AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.. |
|
| DC11542 | AZD-9567 monohydrate | AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.. |
|
| DC9117 | Bambuterol HCl | Bambuterol Hcl is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. |
|
| DC10021 | Batefenterol Featured | Batefenterol（GSK961081，TD-5959）is a Muscarinic Antagonist and β2-Agonist possessing both muscarinic antagonist (MA) and β2-adrenoceptor agonist (BA) properties (MABA). |
|
| DC9632 | BAY 61-3606 (dihydrochloride) Featured | BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. |
|
| DC10660 | BAY 61-3606 free base Featured | BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. |
|
| DC11859 | BAY85-8501 | BAY 85-8501 (BAY85-8501) is a potent, selective human neutrophil elastase (HNE) inhibitor with IC50 of 65 pM. |
|
| DC9956 | BFH772 Featured | BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. |
|
| DC11819 | BMS-986142 Featured | BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). |
|
| DC12030 | BMS-986195 Featured | BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). |
|
| DC7675 | BX-471（ZK 811752） Featured | BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. |
|
| DC10357 | Cenerimod | Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM. |
|
